WFIKKN2 Inhibitors
WFIKKN2 inhibitors refer to a class of chemical compounds designed and developed to specifically target and modulate the activity of the protein known as WFIKKN2. This protein is a member of the WFDC (WAP four-disulfide core) domain-containing protein family, which plays a crucial role in regulating various cellular processes. The development of inhibitors for WFIKKN2 is primarily aimed at gaining a deeper understanding of its biological functions and implications in various physiological contexts.
WFIKKN2 inhibitors typically exert their effects by binding selectively to the WFIKKN2 protein, thereby interfering with its normal function. The mechanism of action of these inhibitors involves disrupting the protein's interactions with its binding partners or altering its structural conformation, which can have downstream effects on cellular processes. The design and synthesis of these inhibitors often involve a thorough understanding of the protein's structure and function, utilizing approaches such as computational modeling, structure-activity relationship studies, and high-throughput screening methods.Research into WFIKKN2 inhibitors may provide valuable insights into the role of WFIKKN2 in cellular biology, signaling pathways, and disease processes. By selectively modulating WFIKKN2 activity, scientists aim to unravel its specific functions and how it contributes to various biological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
Imatinib inhibits the BCR-ABL kinase, blocking phosphorylation of tyrosine residues and disrupting the downstream signaling pathways in chronic myeloid leukemia. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that disrupts tumor angiogenesis by inhibiting VEGFR and RAF kinases, hindering cell proliferation and blood vessel formation in cancer. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib targets the EGFR tyrosine kinase, blocking phosphorylation and downstream signaling, thus inhibiting cell growth in non-small cell lung cancer. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib selectively inhibits the mutant BRAF(V600E) kinase, halting the constitutive activation of the MAPK signaling pathway in melanomas with this mutation. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib is a PARP inhibitor that prevents DNA repair in BRCA-mutated cancer cells, leading to the accumulation of DNA damage and cell death. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus inhibits mTOR, a key regulator of cell growth and proliferation, thereby slowing down the progression of certain cancers like renal cell carcinoma. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib targets BCR-ABL and other kinases, interfering with the growth and survival of leukemia cells in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits both EGFR and HER2 kinases, disrupting signaling pathways in HER2-positive breast cancer cells, leading to cell growth inhibition. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib targets the BTK kinase in B cells, blocking B-cell receptor signaling and disrupting the survival of B-cell malignancies, such as chronic lymphocytic leukemia. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits CDK4/6, leading to cell cycle arrest in hormone receptor-positive breast cancer, preventing cell proliferation and tumor growth. | ||||||